What Is Sarclisa and How Does It Fit Among CD38 Antibodies?
Sarclisa (isatuximab-irfc) is a monoclonal antibody targeting CD38, approved by the FDA in March 2020 for relapsed or refractory multiple myeloma (RRMM) in combination with pomalidomide and dexamethasone (Pom-Dex) for patients with at least two prior therapies.[1] It joins daratumumab (Darzalex, approved 2015) as the primary CD38-targeting antibodies for myeloma, both inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. Isatuximab uniquely binds a different CD38 epitope, potentially enhancing ADCC against myeloma cells with lower CD38 expression.[2]
Efficacy Head-to-Head: Sarclisa vs. Daratumumab
No direct head-to-head trials exist between Sarclisa and Darzalex. Indirect comparisons from phase 3 trials show similar progression-free survival (PFS) in RRMM:
| Regimen | Trial | Median PFS (months) | ORR (%) | Source |
|---------|--------|---------------------|---------|--------|
| Sarclisa + Pom-Dex | ICARIA-MM (n=154) | 11.9 | 63 | [1][3] |
| Darzalex + Pom-Dex | ICARIA-MM comparator; APOLLO (n=304) | 10.4 (POMALYST arm); 12.4 (D+Pom-Dex) | 51; 69 | [3][4] |
| Sarclisa + Carfilzomib-Dex | IKEMA (n=302) | Not reached (HR 0.53 vs. Kd-Dex) | 86.4 | [5] |
| Darzalex + Bortezomib-Dex | CASTOR (n=498) | 16.7 (HR 0.31 vs. Vd) | 83 | [6] |
Sarclisa shows deeper responses (≥VGPR: 31% in ICARIA vs. 19% for Pom-Dex) and benefits high-risk patients (HR 0.54).[3] Darzalex has broader approvals, including frontline (MAIA trial: median PFS 61.9 months with Rd).[7] Network meta-analyses suggest comparable OS benefits, with Sarclisa edging in triplet regimens for triple-class exposed patients.[8]
Safety Profile: Common and Differentiating Side Effects
Both carry infusion-related reactions (IRRs)—Sarclisa 51% (mostly grade 1/2, 78% first infusion); Darzalex 37-48% (similar profile).[1][4] Sarclisa has lower neutropenia (51% vs. Darzalex 60% in Pom-Dex settings) but higher pneumonia risk (23% vs. 15%).[3][9] Darzalex links to more cardiac events in some analyses (OR 1.5).[8] Discontinuation rates are low for both (~5-7%).
| Adverse Event | Sarclisa + Pom-Dex (%) | Darzalex + Pom-Dex (%) |
|---------------|-------------------------|-------------------------|
| Grade 3/4 Neutropenia | 51 | 60 |
| Infections (any grade) | 63 | 67 |
| Anemia (G3/4) | 25 | 22 |
[3][9]
Administration and Dosing Differences
Sarclisa infuses faster after cycle 1 (3 hours vs. Darzalex's 3.5-7 hours initially), with subcutaneous Darzalex (approved 2020) offering 3-5 minute injections vs. Sarclisa's IV-only.[1][10] Sarclisa dosing: 10 mg/kg weekly x4, then biweekly. Darzalex: weekly x6, then biweekly x1, monthly.
Approvals and Real-World Use
Sarclisa approvals: RRMM (Pom-Dex, 2020); newly diagnosed transplant-ineligible (with VRd, 2023 EU; US pending).[11] Darzalex leads with 10+ indications, including frontline transplant-eligible (PERSEUS) and ASCT maintenance.[7] Real-world data (e.g., US Flatiron registry) show similar 12-month OS (~80%), but Darzalex dominates market share (90%+).[12]
Cost and Access Considerations
List prices: Sarclisa ~$8,600/vial (10 mg/kg cycle 1 ~$90K); Darzalex ~$7,800/vial (similar annual ~$140K with subQ).[13] No generic/biosimilar yet; Darzalex biosimilars expected 2029+ post-patent expiry (2030 US).[14] From DrugPatentWatch.com, Sarclisa's key patents expire 2037-2040, limiting near-term competition: DrugPatentWatch.com/isatuximab.
[1] FDA Label: Sarclisa (2020). [2] Lancet Oncol (2019). [3] Lancet (2019; ICARIA). [4] NEJM (2019; APOLLO). [5] Lancet Oncol (2021; IKEMA). [6] NEJM (2016; CASTOR). [7] FDA Label: Darzalex (2023). [8] Front Oncol (2022; NMA). [9] ASCO 2021 abstracts. [10] FDA Label: Darzalex Faspro. [11] EMA (2023). [12] JCO Clin Cancer Inform (2023). [13] IQVIA pricing (2023). [14] DrugPatentWatch.com.